Search
Interferon Gamma
go.drugbank.com/drugs/DB15753InvestigationalThe interferon is primarily produced by activated T lymphocytes and natural killer cells. … Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions.
Disoxaril
go.drugbank.com/drugs/DB08726ExperimentalThis compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
KB3305
go.drugbank.com/drugs/DB06349ExperimentalKB3305 is an investigational liver selective antagonist for the glucocorticoid receptor, developed by Karo Bio for the treatment of Type 2 Diabetes.
Echinacoside
go.drugbank.com/drugs/DB15488Investigational[A184577] Echinacoside has demonstrated inhibition of apoptosis in neural cell lines, demonstrating potential for use in the treatment of neurological conditions.[A184592] … Echinacoside is a phenylethanoid glycoside isolated from _Echinacea angustifolia_ in 1950, and currently being investigated for the treatment of Parkinson's, Alzheimer's, atherosclerosis, osteoporosis,
Tesevatinib
go.drugbank.com/drugs/DB11973InvestigationalTesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. … In cell culture models, tesevatinib retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.
Categories: Receptor, EphB4, antagonists & inhibitors, Receptor, ErbB-2, antagonists & inhibitorsRexin G
go.drugbank.com/drugs/DB16450InvestigationalRexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. … It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.
UC-781
go.drugbank.com/drugs/DB05871InvestigationalIt is a topical microbicide targeted against the AIDS virus.
Darusentan
go.drugbank.com/drugs/DB04883InvestigationalDarusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.
Categories: Endothelin Receptor AntagonistsOtenabant
go.drugbank.com/drugs/DB11745InvestigationalOtenabant has been investigated for the treatment of Obesity.
Categories: Cannabinoid Receptor Antagonists, Receptor, Cannabinoid, CB1, antagonists & inhibitorsEtazolate
go.drugbank.com/drugs/DB05881InvestigationalEHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.